Tags

Type your tag names separated by a space and hit enter

[Pharmacological effects of HMG-CoA reductase inhibitors].
Nihon Rinsho. 2002 May; 60(5):955-61.NR

Abstract

The HMG-CoA reductase inhibitors reduce levels of low-density lipoproteins, raise high-density lipoproteins, and lower triglycerides. Treatment with HMG-CoA reductase inhibitors reduces the risk of cardiovascular events across a broad spectrum of patient profiles, as evidenced by both primary and secondary prevention trials. Improved survival by way of reduced deaths from coronary heart disease was also reported with these agents, which are primarily indicated for substantial reduction in LDL-cholesterol levels. However, HMG-CoA reductase inhibitors are extremely complex drugs and exhibit a wide variety of vascular effects that may or may not be dependent on their lipid-modifying properties. These so-called pleiotropic effects include alternations of endothelial function, inflammation, coagulation and plaque stability. The relative contribution of the nonlipid effects of HMG-CoA reductase inhibitor therapy to the well-documented clinical benefits is currently under intense investigation.

Authors+Show Affiliations

Department of Geriatric Medicine, Osaka University Graduate School of Medicine.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

12029999

Citation

Tomita, Naruya, et al. "[Pharmacological Effects of HMG-CoA Reductase Inhibitors]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 60, no. 5, 2002, pp. 955-61.
Tomita N, Morishita R, Ogihara T. [Pharmacological effects of HMG-CoA reductase inhibitors]. Nippon Rinsho. 2002;60(5):955-61.
Tomita, N., Morishita, R., & Ogihara, T. (2002). [Pharmacological effects of HMG-CoA reductase inhibitors]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 60(5), 955-61.
Tomita N, Morishita R, Ogihara T. [Pharmacological Effects of HMG-CoA Reductase Inhibitors]. Nippon Rinsho. 2002;60(5):955-61. PubMed PMID: 12029999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacological effects of HMG-CoA reductase inhibitors]. AU - Tomita,Naruya, AU - Morishita,Ryuichi, AU - Ogihara,Toshio, PY - 2002/5/28/pubmed PY - 2002/6/22/medline PY - 2002/5/28/entrez SP - 955 EP - 61 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nippon Rinsho VL - 60 IS - 5 N2 - The HMG-CoA reductase inhibitors reduce levels of low-density lipoproteins, raise high-density lipoproteins, and lower triglycerides. Treatment with HMG-CoA reductase inhibitors reduces the risk of cardiovascular events across a broad spectrum of patient profiles, as evidenced by both primary and secondary prevention trials. Improved survival by way of reduced deaths from coronary heart disease was also reported with these agents, which are primarily indicated for substantial reduction in LDL-cholesterol levels. However, HMG-CoA reductase inhibitors are extremely complex drugs and exhibit a wide variety of vascular effects that may or may not be dependent on their lipid-modifying properties. These so-called pleiotropic effects include alternations of endothelial function, inflammation, coagulation and plaque stability. The relative contribution of the nonlipid effects of HMG-CoA reductase inhibitor therapy to the well-documented clinical benefits is currently under intense investigation. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/12029999/[Pharmacological_effects_of_HMG_CoA_reductase_inhibitors]_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.